
Loading, please wait...

Loading, please wait...

Researchers analyzed 141 heart failure patients (HF) undergoing atrial fibrillation (AF) ablation, with 45 receiving SGLT2 inhibitors (SGLT2i). Atrial arrhythmia recurrence was significantly lower in the SGLT2i group. Multivariate analysis confirmed SGLT2i use was associated with reduced recurrence risk. Propensity-matched analysis (24 pairs) supported these findings. SGLT2i may help prevent arrhythmia recurrence after AF ablation in HF patients.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Researchers analyzed 141 heart failure patients (HF) undergoing atrial fibrillation (AF) ablation, with 45 receiving SGLT2 inhibitors (SGLT2i). Atrial arrhythmia recurrence was significantly lower in the SGLT2i group. Multivariate analysis confirmed SGLT2i use was associated with reduced recurrence risk. Propensity-matched analysis (24 pairs) supported these findings. SGLT2i may help prevent arrhythmia recurrence after AF ablation in HF patients.
4 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today